Pre-surgery rehab for obese liver donors with MASLD using Mazdutide
Treatments studied
Part of Digestive system clinical trials.
This trial tests if a medicine called Mazdutide can help overweight living liver donors who have a fatty liver condition (MASLD) lose weight and improve their liver health before donating part of their liver. It aims to make the donation safer and more successful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You are overweight, with a BMI of 24 or higher.
- You have MASLD (fatty liver disease) confirmed by an ultrasound or special scan, with a certain level of fat in your liver.
- A liver biopsy shows you have MASLD but no scarring (fibrosis), and the fat score is at least 2 out of 3.
- You are willing to donate part of your liver to a spouse or blood relative within three generations (like a parent, sibling, or child).
- You can commit to all study visits and procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This study compares two treatments for liver scarring in people with overweight or related health issues. One group follows a special diet with restricted eating times, while the other takes a combination of two medications (naltrexone and bupropion). It aims to see which approach better improves liver fibrosis.
This study looks at factors that predict liver cancer and the need for a liver transplant in people with a liver condition called MASLD (metabolic dysfunction-associated steatotic liver disease). The goal is to better understand the disease and improve care.
This trial tests a new medication called ACT500 for people with fatty liver disease (MASLD). The goal is to see if it is safe and how the body processes it. You may be able to join if you have at least 10% liver fat, some liver scarring or damage, and certain metabolic risk factors like being overweight or having prediabetes.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
This trial tests whether a probiotic mixture can improve liver health in people with moderate fatty liver disease (MASLD). It looks at how the probiotic affects liver fat, inflammation, and metabolism.
Hear when a new Hepatic Steatosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.